Treating Patients With Melanoma and ALK Alterations With Ensartinib
The purpose of this study is to test the effects of the study drug, ensartinib, on the patient and the cancer. Ensartinib is a new, investigational type of treatment for melanoma with a particular type of abnormality.
Melanoma
DRUG: Ensartinib|DIAGNOSTIC_TEST: ALKATI by Customized Nanostring Assay
clinical benefit rate (CBR), CBR is defined as any confirmed objective response by Response Evaluation in Solid Tumor (RECIST) 1.1, or stable disease until the 24 week assessment., up to 24 weeks
The purpose of this study is to test the effects of the study drug, ensartinib, on the patient and the cancer. Ensartinib is a new, investigational type of treatment for melanoma with a particular type of abnormality.